Jeito Capital led a €132m Series B round in Azafaros.

Jeito Capital, a global investment company, led a €132m Series B round in Azafaros, a clinical-stage biotechnology company treating rare lysosomal storage disorders, with participation from Forbion, Seroba, Pictet, Schroders Capital and BGV. “This successful Series B round marks a significant milestone for Azafaros, allowing us to accelerate the development of nizubaglustat and leverage our scientific understanding and competencies to bring additional candidates into development. The fact that we have been able to attract leading life sciences investors to join our existing, strong group of specialist investors is a testament to the impressive accomplishments of the team and the large unmet medical need that currently exists for patients with these hugely debilitating neurological diseases. We look forward to bringing nizubaglustat to patients,” Stefano Portolano, Azafaros CEO.